Saxagliptin Cardiotoxicity in Chronic Heart Failure: The Role of DPP4 in the Regulation of Neuropeptide Tone

Dipeptidyl-peptidase-4 (DPP4) inhibitors are novel medicines for diabetes. The SAVOR-TIMI-53 clinical trial revealed increased heart-failure-associated hospitalization in saxagliptin-treated patients. Although this side effect could limit therapeutic use, the mechanism of this potential cardiotoxici...

Descripción completa

Detalles Bibliográficos
Autores principales: Vörös, Imre, Onódi, Zsófia, Tóth, Viktória Éva, Gergely, Tamás G., Sághy, Éva, Görbe, Anikó, Kemény, Ágnes, Leszek, Przemyslaw, Helyes, Zsuzsanna, Ferdinandy, Péter, Varga, Zoltán V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312997/
https://www.ncbi.nlm.nih.gov/pubmed/35884882
http://dx.doi.org/10.3390/biomedicines10071573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312997/
https://www.ncbi.nlm.nih.gov/pubmed/35884882
http://dx.doi.org/10.3390/biomedicines10071573

Ejemplares similares